Our study revealed unexpected sex‐, tissue‐, and context‐specific aspects of glitazone action which are relevant for the development and personalization of new therapeutic approaches targeting PPARg and adipose tissue metabolism in type 2 diabetes and prediabetes. This evidence concerns the gene PPARG and type 2 diabetes mellitus.